Highlights • The mAbs can neutralize human viruses with help of immune system. • Because of high affinity, mAbs can be designed and engineered against a variety of viral targets. • Antibody fragments are next generation therapeutics against viral infections. Due to the vastness of the science virology, it is no longer an offshoot solely of the microbiology. Viruses have become as the causative agents of major epidemics throughout history. Many therapeutic strategies have been used for these microorganisms, and in this way the recognizing of potential targets of viruses is of particular importance for success. For decades, antibodies and antibody fragments have occupied a significant body of the treatment approaches against infectious diseases. Because of their high affinity, they can be designed and engineered against a variety of purposes, mainly since antibody fragments such as scFv, nanobody, diabody, and bispecific antibody have emerged owing to their small size and interesting properties. In this review, we have discussed the antibody discovery and molecular and biological design of antibody fragments as inspiring therapeutic and diagnostic agents against viral targets.
【저자키워드】 COVID-19, monoclonal antibody, viral infections, biopharmaceuticals, Antibody fragments, Viral targets, 【초록키워드】 Diseases, antibody, Epidemics, diagnostic, immune system, nanobody, therapeutic, target, microorganisms, targets, molecular, therapeutic strategy, mAb, help, high affinity, scFv, neutralize, virus, variety, antibody fragment, recognizing, treatment approach, 【제목키워드】 Antiviral,